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Gupta et al1 present a meta-analysis and conclude that microvolt T-wave alternans testing 
(MTWA) does not modify risk of sudden cardiac death (SCD) sufficiently for clinical use.  Their 
analysis involves a number of methodological limitations. The authors included in their primary 
analysis numerous surrogates for sudden cardiac death (SCD) such as ICD therapy, cardiac 
mortality and total mortality.  It has been demonstrated2,3 that use of such surrogates introduces 
spurious endpoints several fold greater in number than the number of actual SCD events. The 
authors also did not adjust for duration of follow-up - combining equally studies with follow-ups 
ranging from 13 to 52 months. The authors also used historical event rates from studies4,5 not 
included in their meta-analysis to calculate expected event rates rather than using the event rates 
from the studies in the meta-analysis itself.   
 
The authors base their analysis on the likelihood ratio (LR) with the justification that this statistic 
is population independent.  LR, like sensitivity and specificity, is theoretically population 
independent only to the extent that the population is composed of a binary mixture of 
individuals.  In practice, all statistical measures may be population dependent and one cannot 
assume that results from one population may be reliably extrapolated to another. Expected event 
rates bifurcated by test result combined with the expected benefit/risk of the intervention are 
among the most important parameters for clinical decision making. 
 
The most relevant sub-analysis presented by the authors is the one that excluded the surrogate 
endpoints mentioned above.  The authors reported that for this sub-analysis LR+ = 1.79 and LR- 
= 0.34.  Applying these LRs to the SCD annual event rate that the authors derive from SCD-
HeFT4 (more recent than MADIT-II5 data) yields expected annual SCD rates of 5.2% and 1.0%.  
These results match well with the actually measured rates of 4.2% and 0.9% in 1004 patients 
with LVEF <= 0.35 from a recent pooled analysis6.   
 
No study has ever demonstrated a benefit for ICD therapy in a patient population with an SCD 
rate anywhere close to as low a level as 0.9% per year.  ICD implantation itself is associated with 
an in-hospital mortality of approximately 1% and a high complication rate subsequent to 
implantation7.  Conversely, patients with a non-negative MTWA test have SCD event rates 
which are greater than the event rates in the studies for which ICD therapy was demonstrated to 
provide a mortality benefit.  Moreover, ICD therapy has been directly demonstrated to provide a 
mortality benefit only in patients with a non-negative MTWA result but not in patients with a 
negative result8. 
 
Consistent with other analyses3,6,8 the results of Gupta et al1 - when surrogate endpoints are 
excluded - indicate that, in fact, MTWA testing is an accurate and reliable means of guiding anti-
arrhythmic therapy. 
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